company background image
ABCZ.F logo

Abcam OTCPK:ABCZ.F Stock Report

Last Price

US$22.25

Market Cap

US$5.5b

7D

0%

1Y

44.9%

Updated

07 Dec, 2023

Data

Company Financials +

ABCZ.F Stock Overview

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery.

ABCZ.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Abcam plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abcam
Historical stock prices
Current Share PriceUS$22.25
52 Week HighUS$23.80
52 Week LowUS$5.00
Beta0.86
1 Month Change0%
3 Month Change0.68%
1 Year Change44.86%
3 Year Change18.48%
5 Year Change67.29%
Change since IPO222.46%

Recent News & Updates

Recent updates

Shareholder Returns

ABCZ.FUS BiotechsUS Market
7D0%-0.06%2.1%
1Y44.9%9.8%30.4%

Return vs Industry: ABCZ.F exceeded the US Biotechs industry which returned -3.5% over the past year.

Return vs Market: ABCZ.F exceeded the US Market which returned 15.2% over the past year.

Price Volatility

Is ABCZ.F's price volatile compared to industry and market?
ABCZ.F volatility
ABCZ.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: ABCZ.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ABCZ.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,760Alan Hirzelhttps://www.abcam.com

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company’s principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies.

Abcam plc Fundamentals Summary

How do Abcam's earnings and revenue compare to its market cap?
ABCZ.F fundamental statistics
Market capUS$5.52b
Earnings (TTM)US$3.14m
Revenue (TTM)US$476.75m

1,759x

P/E Ratio

11.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABCZ.F income statement (TTM)
RevenueUK£379.70m
Cost of RevenueUK£91.60m
Gross ProfitUK£288.10m
Other ExpensesUK£285.60m
EarningsUK£2.50m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.011
Gross Margin75.88%
Net Profit Margin0.66%
Debt/Equity Ratio16.4%

How did ABCZ.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.